Last reviewed · How we verify

Riluzole (100 mg) — Competitive Intelligence Brief

Riluzole (100 mg) (Riluzole (100 mg)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Glutamate antagonist / Neuroprotective agent. Area: Neurology.

phase 3 Glutamate antagonist / Neuroprotective agent Glutamate release (presynaptic); voltage-gated sodium channels Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Riluzole (100 mg) (Riluzole (100 mg)) — AB Science. Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Riluzole (100 mg) TARGET Riluzole (100 mg) AB Science phase 3 Glutamate antagonist / Neuroprotective agent Glutamate release (presynaptic); voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Glutamate antagonist / Neuroprotective agent class)

  1. AB Science · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Riluzole (100 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/riluzole-100-mg. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: